Ark Genomic Revolution ETF

Quinn Emanuel Fined $3M and Mandated Training for Misleading Court in Natera Case

Beam Therapeutics Presents BEAM-302 Phase 1/2 Data, Plans Accelerated Approval in 2026

Manulife Singapore to Launch Shield™ Multi-Cancer Test with Guardant Health in May 2026

Tempus AI to participate in the 2026 ASCO® Annual Meeting

Tempus AI will host an Investor Day on May 29, 2026

Tempus AI will hold its Annual General Meeting on May 21, 2026

Natera Co-founder Sheena Jonathan Sells Shares in Two Transactions in May

Signatera™ CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Tempus AI to Hold Annual General Meeting on May 20, 2026

Tempus AI to Host Inaugural Investor Day on May 29, 2026

Tempus AI Expands Strategic Collaboration with Bristol Myers Squibb in Oncology and Neuroscience

Illumina CEO joins China delegation, stock price rises

Tempus AI is expected to close its upsized $400 million convertible senior notes offering on May 12

Intellia Therap released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 15.05 M (forecast USD 13.81 M), actual EPS USD -0.8121 (forecast USD -0.8904)

ARK Invest Purchases Over $8 Million Worth of Tempus AI (TEM) Stock

H.C. Wainwright cuts Tempus AI (TEM) stock price target on wider losses

Guardant Health Reports Significant Losses in Q4 2025 Earnings

QRG Capital Management Inc. Significantly Increased Holdings in Natera Inc.

The Motley Fool names Tempus AI as a stock poised to disrupt the healthcare market

Beam Therapeutics released FY2026 Q1 earnings on May 7, 2026 (EST), with actual revenue of USD 31.74 M (forecast USD 12.22 M) and actual EPS of USD -0.9133 (forecast USD -1.0121)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share

ETON

SBIO

ARKG

IBBQ

LABU

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO, agreeing to pay $4.25 million in fixed fees and up to $4 million in sales milestones. Eton will share 55% of annual net sales up to $7 million and 50% above that. The agreement, effective from September 26, 2026, includes a term until March 31, 2032, with potential renewals. Symphony Health projects 2025 U.S. sales of $8.1 million.

TradingView

Eton Pharmaceuticals

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

iShares US Pharma

VanEck Biotech ETF

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

UCBJY

UCB announced positive results from the phase 3 BE BOLD trial, showing bimekizumab outperformed risankizumab in treating active psoriatic arthritis. At week 16, 49.1% of bimekizumab patients achieved ACR50 compared to 38.4% for risankizumab. Early improvements were noted as early as week 4. No new safety concerns were reported, although mild to moderate candida infections were more common with bimekizumab.

PharmaTimes

UCB S.A.

United Community Banks

UCB reports positive outcomes for bimekizumab in psoriatic arthritis

ENTA

Enanta Pharmaceuticals Inc. (ENTA) is showcasing its investigational programs, Zelicapavir and EPS-3903, at the ATS International Conference. Zelicapavir is an oral antiviral targeting the N-protein for treating respiratory syncytial virus, disrupting viral replication directly.

rttnews

Enanta Pharma

Enanta Pharma's RSV Bet And Immunology Ambitions

ADAG

Adagene's Chief Strategy Officer, Mickael Chane-Du, discussed the company's clinical strategy for its lead antibody program, ADG126, focusing on improving CTLA-4 inhibition. ADG126, a masked anti-CTLA-4 antibody, aims to enhance therapeutic efficacy in colorectal cancer, particularly in microsatellite-stable patients without liver metastases. The company is conducting a randomized Phase 2 trial to evaluate ADG126's effectiveness in combination with pembrolizumab, with results expected to guide future trials.

Market Beat

Adagene

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

BAYN

BAYRY

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Bayer AG

Bayer

Nasdaq

Bayer Aktiengesellschaft

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

DRMA

DRMAW

Analyst Anthony Vendetti from Maxim Group has reiterated a Buy rating on Dermata Therapeutics, maintaining a 12-month price target of $4. He cites the company's progress in launching its first skincare product, a disciplined cost structure, and sufficient liquidity into late 2026 as key factors. Despite early-stage risks, Vendetti believes the stock's valuation is attractive relative to its growth potential.

Tip Ranks

Dermata Therapeutics

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM)

Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4

IMRX

Chardan Capital analyst Geulah Livshits has reiterated a Buy rating on Immuneering (IMRX) with a price target of $20.00. Livshits, who focuses on the Healthcare sector, has an average return of 7.8% and a 35.98% success rate on recommended stocks. Mizuho Securities also maintained a Buy rating on the stock, setting a price target of $12.00.

Immuneering

Palvella Therapeutics

Iovance Biotherapeautics

Tenaya Therapeutics

Mizuho Financial

Mizuho Financial Group, Inc.

Immuneering (IMRX) Gets a Buy from Chardan Capital

OGEN

Oragenics has initiated Phase IIa dosing of ONP-002 in Australia, with a cash balance of $6.1M and a Letter of Intent for a CNS device. The trial involves 40 patients and focuses on safety and feasibility, with no serious adverse events reported. The company plans to request an FDA Type C meeting in Q2 2026 and aims for a full IND submission by the end of 2026. R&D expenses have increased by 89% to $0.6M, and an annual meeting is scheduled for June 29, 2026.

Oragenics

Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device

GILD

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Gilead Sciences

Gilead Sciences, Inc.

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

Wave Life Sciences announced positive results from the RestorAATion-2 trial, showing that WVE-006 effectively restores M-AAT levels and reduces Z-AAT levels. In the 200 mg biweekly cohort, M-AAT reached 64% of total, while Z-AAT decreased by 71%. The 400 mg monthly dosing also showed significant results. The treatment was well tolerated with no liver toxicities. The company anticipates FDA feedback on accelerated approval by mid-2026 and plans to present further data in H2 2026.

Wave Life Sciences

Bioshares Biotech Clinical Trials Fd

Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing

NTHI

NeOnc Technologies Holdings, Inc. reported progress in its glioma programs, completing a Phase 1 study of NEO212 and enrolling in a Phase 2a trial of NEO100. The company improved its financial position with a $10 million PIPE financing and reduced its quarterly net loss to $8.8 million. Analysts rate NTHI stock as a Buy with a $20.00 target, though concerns about financial performance persist. NeOnc focuses on CNS cancers, developing drugs under FDA Fast-Track status.

Neonc Tech

NeOnc Advances Glioma Programs and Strengthens Financial Position

Ark Genomic Revolution ETF(ARKG.US)